Deals
Drug-Trial Software Maker Clario Files Confidentially for IPO
- Clario targets valuation of more than $10 billion, sources say
- Private equity-backed company looking to list next year
This article is for subscribers only.
Clario, a provider of software to help drugmakers advance treatments through clinical trials, has filed confidentially for an initial public offering and is targeting a valuation of more than $10 billion, people familiar with the matter said.
The Philadelphia-based company is working with underwriters including JPMorgan Chase & Co., Morgan Stanley, Jefferies Financial Group Inc. and UBS Group AG, according to the people. It’s targeting next year for a listing, one of the people said.